Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:abuseDeterrent |
yes
|
| gptkbp:activeIngredient |
gptkb:oxycodone
|
| gptkbp:approvalYear |
2016
|
| gptkbp:ATCCode |
N02AA05
|
| gptkbp:blackBoxWarning |
addiction, abuse, misuse, overdose, respiratory depression
|
| gptkbp:compatibleWith |
as-needed pain relief
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:form |
capsule
extended-release capsule |
| gptkbp:genericName |
gptkb:oxycodone
|
| gptkbp:halfLife |
4.5 hours (oxycodone)
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xtampza ER
|
| gptkbp:indication |
pain management
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Collegium Pharmaceutical
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:releaseMechanism |
extended-release
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
chronic pain
|
| gptkbp:website |
https://www.xtampzaer.com/
|
| gptkbp:bfsParent |
gptkb:oxycodone_extended-release
|
| gptkbp:bfsLayer |
8
|